A traditional Chinese medicine composition for treating psoriasis, a preparation method therefor and a use thereof. The traditional Chinese medicine composition comprises: water buffalo horn powder, Japanese honeysuckle flower, gypsum, red peony root, peony bark, charred cape jasmine fruit, baical skullcap root, raw garden burnet root, and liquorice root. The preparation method comprises: proportionally weighing out the baical skullcap root, the Japanese honeysuckle flower, the red peony root, the peony bark, the gypsum, the charred cape jasmine fruit, the garden burnet root and the liquorice root, adding water and decocting 1 to 3 times, each time using 4 to 10 times the amount (weight to volume ratio) of water and decocting for 0.5 to 3 hours; combining decoctions, filtering, vacuum concentrating the filtrate, drying same, adding the water buffalo horn powder and mixing until evenly distributed.

Methods for inactivating in a cell a mutant allele of the elastase, neutrophil expressed gene (ELANE gene) gene having a mutation associated with severe congenital neutropenia (SCN) or cyclic neutropenia (CyN) and which cell is heterozygous at one or more polymorphic sites selected from the group consisting of: rs10424470, rs4807932, rs10414837, rs376107533, rs3761010, rs351108, rs3826946, rs10413889, rs3761007, rs10409474, rs3761005, rs351107, rs3761001, rs740021, rs781452480, rs371057361, rs570466264, rs1041904080, rs7250194, rs17216649, rs199720952, rs6510983, rs17223066, rs7255385, rs9749274, rs111361200, rs112639467, rs141213775, rs28591229, rs10469327, rs3834645, rs1683564, rs71335276, and rs8107095, the method comprising introducing to the cell a composition comprising: a CRISPR nuclease or a sequence encoding the CRISPR nuclease; and a first RNA molecule comprising a guide sequence portion having 21-30 nucleotides, wherein a complex of the CRISPR nuclease and the first RNA molecule affects a double strand break in the mutant allele of the ELANE gene.

Methods for inactivating in a cell a mutant allele of the elastase, neutrophil expressed gene (ELANE gene) gene having a mutation associated with severe congenital neutropenia (SCN) or cyclic neutropenia (CyN) and which cell is heterozygous at one or more polymorphic sites selected from the group consisting of: rs10424470, rs4807932, rs10414837, rs376107533, rs3761010, rs351108, rs3826946, rs10413889, rs3761007, rs10409474, rs3761005, rs351107, rs3761001, rs740021, rs781452480, rs371057361, rs570466264, rs1041904080, rs7250194, rs17216649, rs199720952, rs6510983, rs17223066, rs7255385, rs9749274, rs111361200, rs112639467, rs141213775, rs28591229, rs10469327, rs3834645, rs1683564, rs71335276, and rs8107095, the method comprising introducing to the cell a composition comprising: a CRISPR nuclease or a sequence encoding the CRISPR nuclease; and a first RNA molecule comprising a guide sequence portion having 21-30 nucleotides, wherein a complex of the CRISPR nuclease and the first RNA molecule affects a double strand break in the mutant allele of the ELANE gene.

Provided are a method of overexpressing a target gene and/or a method of reprogramming cells, the method including steps of (a) introducing a vector into cells, into which vector a promoter and a target gene are inserted; and (b) applying an electromagnetic wave to the cells obtained in the step (a), and a method of treating a disease using the method.

When the method of overexpressing a target gene using the electromagnetic wave-reactive promoter of the present disclosure is used, it is possible to artificially regulate expression levels of desired target genes in a simple manner in vivo and in vitro and to regulate expression of the target genes until a desired predetermined time.

Provided are a method of overexpressing a target gene and/or a method of reprogramming cells, the method including steps of (a) introducing a vector into cells, into which vector a promoter and a target gene are inserted; and (b) applying an electromagnetic wave to the cells obtained in the step (a), and a method of treating a disease using the method.

When the method of overexpressing a target gene using the electromagnetic wave-reactive promoter of the present disclosure is used, it is possible to artificially regulate expression levels of desired target genes in a simple manner in vivo and in vitro and to regulate expression of the target genes until a desired predetermined time.

Multiple component grafts are provided for treatment of tissue defects and comprise two or more components, each of which is a tissue-derived matrix and at least two of which are derived from different types of tissue. For example, a first component may be a matrix derived from cartilage tissue such as cartilage fibers with or without viable cells, cartilage particles with or without viable cells, or combinations of any two or more such cartilage-derived matrices. A second component may be a matrix derived from bone tissue such as mineralized or demineralized cortical bone fibers, viable cancellous bone matrix (e.g., cryopreserved or lyophilized chips, particulates, powder, sheets, putty, flowable fluid, etc.), demineralized or demineralized cancellous bone matrix (chips, particulates, powder, sheets, putty, flowable fluid, etc.), or combinations of any two or more of such bone-derived matrices. Also provided are methods for making and using such multiple component grafts.

Disclosed are various bioactive grafts and methods of making the same. In one embodiment, bone material is harvested from a donor. The harvested bone material is exposed to a lysing agent, the lysing agent configured to release growth factors and bioactive materials from cellular material of the harvested bone material. The harvested bone material is then rinsed with a rinsing agent. The pH of the harvested bone material is substantially neutralized.

Disclosed are various bioactive grafts and methods of making the same. In one embodiment, bone material is harvested from a donor. The harvested bone material is exposed to a lysing agent, the lysing agent configured to release growth factors and bioactive materials from cellular material of the harvested bone material. The harvested bone material is then rinsed with a rinsing agent. The pH of the harvested bone material is substantially neutralized.

A dental tissue regenerative composition. The composition includes a combination of (1) human dental pulp stem cells and (2) at least one of human umbilical vein endothelial cells or vascular endothelial growth factor. The combination is encapsulated in a light-activated gelatin methacrylate hydrogel.

Disclosed are various bioactive grafts and methods of making the same. In one embodiment, bone material is harvested from a donor. The harvested bone material is exposed to a lysing agent, the lysing agent configured to release growth factors and bioactive materials from cellular material of the harvested bone material. The harvested bone material is then rinsed with a rinsing agent. The pH of the harvested bone material is substantially neutralized.